Our teams coordinate best-in-class investigational, regulatory, intellectual property and commercialization strategies to move promising development stage drugs through regulatory approval with fresh new patents.
We target therapies in late stage pre-clinical or early clinical development at research organizations, universities and university spin-out companies who lack commercialization experience.
We leverage our proven in-house patent evergreening strategies with best-in-class formulation and clinical research organizations to bring high value therapeutics to market.
We target high value therapeutics that harness the body's natural regenerative pathways to reduce harmful inflammation and promote tissue regeneration.
We target therapies that stimulate the patient's immune system, activating the body's natural defense mechanisms to fight malignancies and to protect normal cells.
We target interventions in myocardial regeneration including endogenous modulators of stem cells and angiogenic factors.
Strategic Planning, Business Development and Commercialization Lead
Building on an award-winning career in biomedical product sales, Jane Lea's expertise is in the transitioning of game changing technologies into high value commercial products. She led the early commerical development and launch of AlloDerm® regenerative technology for LifeCell Corporation, acquired by Allergan for $2.8 billion in 2017. https://www.linkedin.com/in/jane-lea-hicks/
Intellectual Property and Pharmacology Lead
John has over 20 years of experience as a U.S. patent attorney and specializes in evergreening pharmaceutical patents. He earned his PhD in Pharmacology and has conducted advanced research in neuroscience at Duke University and Burroughs Welcome. https://www.linkedin.com/in/johnweatherspoon/
Medicinal Chemistry Team Lead
Dr. Swain has more than 25 years experience as a scientist/inventor and intellectual property specialist. In his prior role as Medicinal Chemist Group Leader at ImmuLogic Pharmaceutical Corporation, Waltham, MA, Dr. Swain created and managed the company’s first medicinal chemistry laboratory and department. He earned his PhD in Synthetic Organic Chemistry from the University of Salford, UK and completed postdoctoral studies at the University of California, San Diego, CA and The University of Texas Southwestern Medical Center at Dallas, TX. Dr. Swain is also a U.S. and Canadian patent agent. https://www.linkedin.com/in/philip-swain-b4590a2/
THIS WEBSITE CONTAINS FORWARD LOOKING STATEMENTS
All statements in this website and attached documents, including videos, are not historical facts and are forward-looking statements which involve risks and uncertainties; actual results may differ from the forward-looking statements. Sentences or phrases which use such words as “projected”, “expect”, “believe”, “anticipates”, “hopeful”, “looking”, “market penetration”, “goal”, “target”, “hopeful”, “should”, “working to”, “working toward”, ” pro-forma”, “developing”, “develop”, “research, “investing” and others indicate forward-looking statements, but their absence does not mean that a statement is not forward-looking. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
These forward looking statements and projections should not be relied upon, but are provided only to show a theoretical outcome. Actual results may be materially different. We cannot and do not warrant the accuracy, completeness or timeliness of the information contained therein. The statements in this document are not historical facts and are forward-looking statements which involve risks and uncertainties; actual results may differ from the forward-looking statements. Sentences or phrases that use such words as “pro-forma”, “projection”, “anticipates”, “attempt”, “target”, “develop”, “working to”, “working toward” and others indicate forward-looking statements, but their absence does not mean that a statement is not forward-looking. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
We caution you that a number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.
For further information, please contact us at:
Email: info@affirmedpharma.com